Zach Rome is a prominent figure in the healthcare industry with a strong focus on developing innovative healthcare products.

In 2013, Zach co-founded Patagonia Pharmaceuticals, aiming to create treatments for rare dermatologic diseases. He served as the lead inventor on all of the company's technologies and supervised their progression from concept to Phase 2 studies.

In 2019, Patagonia Pharmaceuticals merged with TardiMed Sciences, leading to the formation of Timber Pharmaceuticals. Timber acquired most of Patagonia's assets, and Zach Rome became affiliated with both Timber Pharmaceuticals and TardiMed Sciences.

Zach's educational background includes a Bachelor of Science (BS) in Marine Science and Biology with a minor in Chemistry from the University of Miami. He pursued further studies, earning a Master of Science in Teaching (MST) in Adolescent Science - Biology with an impressive GPA of 4.0 from Pace University.

Zach Rome has held key positions in various organizations, notably as a Partner at TardiMed Sciences, Co-Founder, COO, & Director at Timber Pharmaceuticals, COO & Director at PaxMedica, and Co-Founder & President at Patagonia Pharmaceuticals, LLC. His roles have spanned across different aspects of these companies, showcasing his versatility and expertise.

Zach Rome's remarkable professional journey also includes roles as Principal at TardiMed Sciences, Co-Founder, President, and Director at Timber Pharmaceuticals, and Co-Founder & Executive Vice President at Patagonia Pharmaceuticals, LLC. Additionally, he served as Co-Founder & Vice President of Business Development at Patagonia Pharmaceuticals, LLC, reflecting his dedication to driving growth and innovation within the healthcare sector.